[HTML] plos.org

[HTML][HTML] Network meta-analysis of erlotinib, gefitinib, afatinib and icotinib in patients with advanced non-small-cell lung cancer harboring EGFR mutations

W Liang, X Wu, W Fang, Y Zhao, Y Yang, Z Hu, C Xue… - PloS one, 2014 - journals.plos.org
Background Several EGFR-tyrosine kinase inhibitors (EGFR-TKIs) including erlotinib,
gefitinib, afatinib and icotinib are currently available as treatment for patients with advanced …
被引用次数：165 相关文章
[PDF] researchgate.net

[PDF][PDF] Network Meta-Analysis of Erlotinib

W Liang, X Wu, W Fang, Y Zhao… - Gefitinib, Afatinib and …, 2014 - researchgate.net
Background: Several EGFR-tyrosine kinase inhibitors (EGFR-TKIs) including erlotinib,
gefitinib, afatinib and icotinib are currently available as treatment for patients with advanced …

Network Meta-Analysis of Erlotinib, Gefitinib, Afatinib and Icotinib in Patients with Advanced Non-Small-Cell Lung Cancer Harboring EGFR Mutations

W Liang, X Wu, W Fang, Y Zhao, Y Yang, Z Hu… - PLOS …, 2014 - econpapers.repec.org
Background: Several EGFR-tyrosine kinase inhibitors (EGFR-TKIs) including erlotinib,
gefitinib, afatinib and icotinib are currently available as treatment for patients with advanced …

Network meta-analysis of erlotinib, gefitinib, afatinib and icotinib in patients with advanced non-small-cell lung cancer harboring EGFR mutations.

W Liang, X Wu, W Fang, Y Zhao, Y Yang, Z Hu, C Xue… - Plos one, 2014 - europepmc.org
Background Several EGFR-tyrosine kinase inhibitors (EGFR-TKIs) including erlotinib,
gefitinib, afatinib and icotinib are currently available as treatment for patients with advanced …

Network meta-analysis of erlotinib, gefitinib, afatinib and icotinib in patients with advanced non-small-cell lung cancer harboring EGFR mutations

W Liang, X Wu, W Fang, Y Zhao, Y Yang, Z Hu… - PloS …, 2014 - pubmed.ncbi.nlm.nih.gov
Background Several EGFR-tyrosine kinase inhibitors (EGFR-TKIs) including erlotinib,
gefitinib, afatinib and icotinib are currently available as treatment for patients with advanced …

[引用][C] Network Meta-Analysis of Erlotinib, Gefitinib, Afatinib and Icotinib in Patients with Advanced Non-Small-Cell Lung Cancer Harboring EGFR Mutations

W Liang, X Wu, W Fang, Y Zhao, Y Yang, Z Hu… - PLoS …, 2014 - ui.adsabs.harvard.edu
Network Meta-Analysis of Erlotinib, Gefitinib, Afatinib and Icotinib in Patients with Advanced
Non-Small-Cell Lung Cancer Harboring EGFR Mutations - NASA/ADS Now on home page ads …
[PDF] scienceopen.com

[PDF][PDF] Network Meta-Analysis of Erlotinib

W Liang, X Wu, W Fang, Y Zhao… - Gefitinib, Afatinib and …, 2014 - scienceopen.com
Background: Several EGFR-tyrosine kinase inhibitors (EGFR-TKIs) including erlotinib,
gefitinib, afatinib and icotinib are currently available as treatment for patients with advanced …

[引用][C] Network meta-analysis of erlotinib, gefitinib, afatinib and icotinib in patients with advanced non-small-cell lung cancer harboring EGFR mutations.

W Liang, X Wu, W Fang, Y Zhao, Y Yang, Z Hu, C Xue… - PLos One, 2014 - scholarmate.com
BACKGROUND: Several EGFR-tyrosine kinase inhibitors (EGFR-TKIs) including erlotinib,
gefitinib, afatinib and icotinib are currently available as treatment for patients with advanced …
[PDF] psu.edu

[PDF][PDF] Network Meta-Analysis of Erlotinib

W Liang, X Wu, W Fang, Y Zhao, Y Yang - Gefitinib, Afatinib and Icotinib …, 2014 - Citeseer
Background: Several EGFR-tyrosine kinase inhibitors (EGFR-TKIs) including erlotinib,
gefitinib, afatinib and icotinib are currently available as treatment for patients with advanced …
[PDF] semanticscholar.org

[PDF][PDF] Network Meta-Analysis of Erlotinib

W Liang, X Wu, W Fang, Y Zhao… - Gefitinib, Afatinib and …, 2014 - pdfs.semanticscholar.org
Background: Several EGFR-tyrosine kinase inhibitors (EGFR-TKIs) including erlotinib,
gefitinib, afatinib and icotinib are currently available as treatment for patients with advanced …